BRIEF—Gilead lays off 150 salespeople

California’s Gilead Sciences is reportedly firing 150 salespeople, as two of its major cardiopulmonary therapies face patent expiration.

The move will see the firm lose around a fifth of its total sales force, in the face of looming generic competition for its Letairis (ambrisentan) and Ranexa (ranolazine) products.

The layoffs are part of a cost-cutting plan the company initiated in 2017.